JBC Transcription and Nuclear Factor Monoclonals

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M103577200 on May 29, 2001

J. Biol. Chem., Vol. 276, Issue 30, 28029-28036, July 27, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/30/28029    most recent
M103577200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huggins, G. S.
Right arrow Articles by Leiden, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huggins, G. S.
Right arrow Articles by Leiden, J. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Friend of GATA 2 Physically Interacts with Chicken Ovalbumin Upstream Promoter-TF2 (COUP-TF2) and COUP-TF3 and Represses COUP-TF2-dependent Activation of the Atrial Natriuretic Factor Promoter*

Gordon S. HugginsDagger §, Christopher J. Bacani||, Jay Boltax||, Ryuichi Aikawa||, and Jeffrey M. Leiden**

From the || Cardiovascular Biology Laboratory, Harvard School of Public Health, Dagger  Cardiac Unit, Massachusetts General Hospital, and § Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, and ** Abbott Laboratories, Abbott Park, Illinois 60064

Received for publication, April 23, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Friend of GATA (FOG)-2 is a multi-zinc finger transcriptional corepressor protein that binds specifically to GATA4. Gene targeting studies have demonstrated that FOG-2 is required for normal cardiac morphogenesis, including the development of the coronary vasculature, left ventricular compact zone, and heart valves. To better understand the molecular mechanisms by which FOG-2 regulates these cardiac developmental programs, we screened a mouse day 11 embryo library using a yeast two-hybrid interaction trap with the fifth and sixth zinc fingers of FOG-2 as bait. Using this approach, we isolated clones encoding the orphan nuclear receptors chicken ovalbumin upstream promoter-transcription factor (COUP-TF) 2 and COUP-TF3. COUP-TF2-null embryos die during embryonic development with defective angiogenesis and cardiac defects, a pattern that partly resembles the FOG-2-null phenotype. The interaction between COUP-TF2 and FOG-2 in mammalian cells was confirmed by co-immunoprecipitation of these proteins from transfected COS-7 cells. The sites of binding interaction between COUP-TF2 and FOG-2 were mapped to zinc fingers 5 and 6 and fingers 7 and 8 of FOG-2 and to the carboxyl terminus of the COUP-TF proteins. Binding to COUP-TF2 was specific because FOG-2 did not interact with the ligand-binding domains of retinoid X receptor alpha , glucocorticoid receptor, and peroxisome proliferating antigen receptor gamma , which are related to the COUP-TF proteins. Full-length FOG-2 markedly enhanced transcriptional repression by GAL4-COUP-TF2(117-414), but not by a COUP-TF2 repression domain mutant. Moreover, FOG-2 repressed COUP-TF2dependent synergistic activation of the atrial natriuretic factor promoter by both GATA4 and the FOG-2-independent mutant GATA4-E215K. Taken together, these findings suggest that FOG-2 functions as a corepressor for both GATA and COUP-TF proteins.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Transcriptional cofactors that bind multiple DNA-binding proteins can broadly affect the transcription of and developmental programs underlying mammalian organogenesis (1). The nuclear proteins Friend of GATA (FOG)1-1 and FOG-2 are multi-zinc finger transcriptional corepressors that bind specifically to members of the GATA family of transcription factors. FOG-1 is required for normal erythroid and megakaryocyte development (2-4), whereas FOG-2 is required for cardiac development (5, 6). Mammalian FOG-1 and FOG-2 originate from a single ancestral gene represented by the Drosophila gene Ush. FOG-1/FOG-2/Ush have both CCHH zinc fingers, commonly regarded as RNA and DNA binding structures, and a distinct subclass of zinc fingers identified by the CCHC motif that bind to protein (7). The location and the tertiary structure of the CCHC fingers within the FOG-1/FOG-2/Ush molecules are conserved, suggesting that the multiple zinc fingers have distinct functions that have been retained during evolution (8).

The FOG-1/FOG-2 proteins were first identified by their interaction with the GATA family of transcription factors, which have two CCCC zinc fingers (9-11). The GATA carboxyl zinc finger binds the WGATAR DNA element and transcription factors including the cardiac homeobox protein Nkx2.5 (12, 13). The amino zinc finger stabilizes DNA binding and also binds the FOG-1/FOG-2 CCHC zinc fingers (9). Among the FOG-2 CCHC zinc fingers, the GATA proteins bind zinc fingers 1 and 6 strongly and fingers 5 and 8 weakly but do not bind to finger 7 (8, 14). Conserved amino acids required for binding have been identified within the first zinc finger of FOG-1 and the amino zinc finger of GATA (14). GATA proteins do not bind the FOG-2 CCHH fingers.

FOG-1 is co-expressed with GATA1, GATA2, and GATA3 in hematopoietic cells (2, 4), whereas FOG-2 is co-expressed with GATA4, GATA5, and GATA6 in the developing heart (9-11). GATA cis-acting elements in the Na+-Ca2+ exchanger (15), cardiac troponin C (16), Nkx2.5 (17, 18), and m2 muscarinic acetylcholine receptor (19) gene promoters are necessary for cardiac-specific transcription. GATA4-deficient embryos die during early development with abnormal ventral morphogenesis and failure to form a linear heart tube (20, 21). Murine FOG-2 is expressed after GATA4, initially in the septum transversum at embryonic day 8.5 and later throughout the heart (9-11). Transient transfection assays have demonstrated that FOG-2 represses activation of numerous cardiac-specific promoters by GATA4, but not by the cardiac homeobox protein Nkx2.5 (22).

In Drosophila, Ush is co-expressed in the cardiogenic mesoderm with the GATA homologue pannier. Loss of Ush results in overproduction of cardiac and precardiac cells, whereas Ush overexpression inhibits cardioblast formation (23). Drosophila cardioblasts harboring hypomorphic and null Ush alleles have impaired cell migration, whereas embryos transheterozygous for Ush showed excessive migration. FOG-2-null mice die during embryonic development with complex cardiac defects including tricuspid atresia, pulmonic stenosis, atrial septal defect, ventricular septal defect, hypoplasia of the left ventricular compact zone, and absent coronary vessel formation (5, 6). The complex valvular and septal abnormalities suggest impaired migration of nonproliferating myocardial cells into the superior and inferior atrioventricular cushions. In response to inductive signals from the myocardium, subpopulations of proepicardial and epicardial cells undergo an epithelial-mesenchymal transformation and invade the myocardium to form the coronary vessels. The absent coronary vasculature and tricuspid valve in FOG-2-null embryos likely reflect the loss of FOG-2-dependent mesenchymal signaling and migration (5, 6).

The molecular mechanism(s) underlying the congenital heart defects seen in FOG-2-deficient mice is poorly understood. Although these abnormalities may reflect dysregulation of a purely GATA-dependent transcriptional program, we hypothesized that the complex phenotype might alternatively reflect a loss of FOG-2 interaction with additional families of transcription factors. To address this possibility, we screened a mouse embryonic day 11 library using a FOG-2 bait in a yeast two-hybrid interaction trap. Using this approach, we isolated clones encoding the orphan nuclear receptors COUP-TF2 and COUP-TF3 (24-26). COUP-TF2 is required for development of the sinus venosus and cardiac atrium beyond a primitive tube, as well as for remodeling of the primitive capillary plexus (27). Like FOG-2, the cardiovascular abnormalities in COUP-TF2-null embryos demonstrate an important role of COUP-TF2 in mesenchymal-endothelial and -epithelial interactions (27). This report details our studies on the molecular interaction of FOG-2 with COUP-TF2, in which we demonstrate that FOG-2 can serve as a corepressor protein for COUP-TF2 in addition to GATA4.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Gene Constructs-- Using oligonucleotide primers, we cloned nucleotides 1761-2764 of FOG-2 in-frame with the GAL4 DNA-binding domain cDNA in the pBD-GAL4-CAM (Stratagene) and the pM (CLONTECH) vectors to produce GAL4-FOG-2(amino acid (aa) 497-831) fusion proteins. GST-FOG-2 fusion proteins were produced from pGEX plasmids encoding fragments of FOG-2 from the amino terminus (aa 31-248), the first four zinc fingers (F1-4, aa 234-399), the fifth and sixth zinc fingers (F5-6, aa 533-724), the sixth zinc finger (F6, aa 668-724), and the seventh and eighth zinc fingers (F7-8, aa 848-1152). Full-length FOG-2 cloned into the BamHI site of the pcDNA3 vector was used for expression in eukaryotic cells (9). pM-FOG-2(aa 497-831)-C571S (M5F6) and -C692S (F5M6) were made using site-directed polymerase chain reaction-based mutagenesis using synthetic oligonucleotide primers (Table I). pM-FOG-2(aa 497-831)-C571S-C692S (M5M6) was made by cloning the 3' HindIII fragment from pM-FOG-2(aa 497-831)-C692S into pM-FOG-2(aa 497-831)-C571S. All constructs were sequenced using standard techniques.

                              
View this table:
[in this window]
[in a new window]
 
Table I
COUP-TF2 interacts with FOG-2

PACT2-COUP-TF2(aa 117-414) and pACT2-COUP-TF3(162-390) were cloned from the Mouse 11-day Embryo MATCHMAKER cDNA library (CLONTECH). Using the oligonucleotide primer COUP-TF2-ATG (Table I), the 5' end of COUP-TF2 was cloned into the EcoRI site of pM. The BstX1 restriction digest fragment of COUP-TF2 was cloned into this vector to create full-length pM-COUP-TF2(1-414) (full-length COUP-TF plasmids were kindly provided by W. Kruijer (26)). The BamHI/XhoI fragment of pACT2-COUP-TF2(aa 117-414) was cloned into pM to make pM-COUP-TF2(117-414). Truncated mutants pM-COUP-TF2(1-335) and pM-COUP-TF2(117-335) were made by removal of the 3' HindIII fragment. EcoRI/XbaI COUP-TF2 fragments from the pM plasmids were then cloned into pVP16 to make pVP16-COUP-TF2(1-414), pVP16-COUP-TF2(117-414), and pVP16-COUP-TF2(117-377). Similar cloning techniques were used to make pcDNA3.1-His-COUP-TF2 (Invitrogen) for in vitro transcription/translation and for eukaryotic expression. The pM- and pVP16-COUP-TF2-(117-414)-L364R-L365S-L367F constructs were produced using the QuikChange Site-directed Mutagenesis Kit (Stratagene) with the COUP-TF-Mut primers (Table I). cDNA coding regions of COUP-TF1 and COUP-TF3, kindly provided by W. Kruijer (26), were subcloned into pCR3 (Invitrogen) for in vitro transcription and translation.

PACT2-PPARgamma (aa 151-475) was made by cloning the BamHI/SalI fragment of the PPARgamma cDNA into pACT2. Mouse RXRalpha was cloned by reverse transcription-polymerase chain reaction, and then the NcoI fragment was used to clone pACT2-RXRalpha (aa 204-446). PSG5-RXRalpha was kindly provided by Soo Jong Um (Sejong University, Seoul, Korea). pACT2-GR-(aa 393-783) was cloned using reverse transcription-polymerase chain reaction with custom-designed oligonucleotide primers. GATA4 and GATA4-E215K cloned into pcDNA3 were used as described previously (22).

Yeast Two-hybrid Assay-- A single clone of AH109 harboring pBD-GAL4-CAM-FOG2(aa 497-831) was expanded and transformed with the Mouse 11-day Embryo MATCHMAKER cDNA library. Library plasmids from clones demonstrating histidine and adenine auxotrophy and beta -galactosidase staining were isolated and sequenced using standard techniques. For interaction assays, a clone harboring the bait plasmid was transformed with pACT2, pACT2-COUP-TF2(aa 117-414), pACT2-COUP-TF3(aa 162-390), pACT2-RXRalpha -(aa 204-466), pACT2-PPARgamma -(aa 151-475), or pACT2-GR-(aa 393-783). For each transformation, three separate clones were isolated on selection plates lacking tryptophan and leucine. beta -Galactosidase activity was measured using a liquid assay, as described previously (28).

Co-immunoprecipitation-- COS-7 cells transfected with expression plasmids using the Superfect transfection reagent (Qiagen) were harvested 24-48 h after transfection in radioimmune precipitation buffer (28) supplemented with the Complete mixture of protease inhibitors (Roche Molecular Biochemicals). Preimmune or immune rabbit antisera was mixed with clarified cell extract and radioimmune precipitation buffer supplemented with 1 mg/ml bovine serum albumin for at least 1 h, followed by precipitation with protein A-agarose beads (Roche Molecular Biochemicals). After washing in radioimmune precipitation buffer three times on ice, proteins were eluted with sample buffer, subjected to 8% SDS-polyacrylamide gel electrophoresis, and blotted onto nitrocellulose. The membrane was then divided, and the upper half was probed with dilute FOG-2 antisera, and the lower half was probed with anti-X-press (Invitrogen) followed by anti-rabbit or anti-mouse IgG-horseradish peroxidase. The chemiluminescent image was developed on Kodak BioMax MR film.

GST Pull-down Assay-- Recombinant COUP-TF1, COUP-TF2, COUP-TF3, RXRalpha , GATA4, and luciferase were expressed and labeled with [35S]methionine (Amersham Pharmacia Biotech) by using the TnT T7 Coupled Reticulocyte System (Promega). Labeled proteins were mixed with glutathione-Sepharose 4B (Amersham Pharmacia Biotech) beads coated with GST fusion proteins in 50 mM NaCl, 0.1% Nonidet P-40, 1 mg/ml bovine serum albumin, 0.25% beta -mercaptoethanol, and 10 µM ZnSO4 for 30 min. The beads were washed in phosphate-buffered saline and 0.1% Nonidet P-40. The proteins were eluted with sample buffer and separated by 15% SDS-polyacrylamide gel electrophoresis, and the dried gel was used for autoradiography with Kodak BioMax MR film.

Transfection-- NIH 3T3, COS-7, and CV-1 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Summit, Fort Collins, CO), 100 units/ml penicillin, and 100 µg/ml streptomycin in a humidified atmosphere at 37 °C with 5% CO2. 293 cells were cultured in the same medium supplemented with 20 mM HEPES and 1 mM nonessential amino acids. Transient transfection assays were performed in 12- or 24-well dishes with 50 ng of reporter plasmid, and a total of 225 ng of expression plasmid and 25 ng of cytomegalovirus beta -galactosidase served as a control for transfectional efficiency. At 24-48 h after transfection, cellular extracts were harvested in Reporter Lysis Buffer (Promega), and luciferase activity was measured on a luminometer (Autolumat 953; EG&G, Gaithersburg, MD) using the Promega luciferase system; beta -galactosidase activity was measured by conversion of o-nitrophenyl beta -D-galactopyranoside. Each sample was performed in triplicate, and each experiment was repeated at least three times.

Statistical Analysis-- The mean and standard error of the mean were determined for replicate samples. For multiple treatment groups, a factorial analysis of variance was applied followed by Fisher's least significant difference test. A p value of less than 0.05 was considered significant.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cloning of COUP-TF2 and COUP-TF3 by Yeast Two-hybrid Library Screen-- Using the fifth and sixth zinc fingers of FOG-2 as bait, we screened 1.2 million clones of a mouse embryonic day 11 library for novel interacting partners. Twenty-four clones demonstrated histidine and adenine auxotrophy and beta -galactosidase activity. Clone 3 encoded part of the DNA-binding domain and the ligand-binding domain of COUP-TF2 (nucleotides 496-1560, aa 117-414), whereas clone 11 encoded the putative ligand-binding domain of COUP-TF3 (nucleotides 689-1734, aa 162-390) (Fig. 1A). Northern analysis confirmed co-expression of FOG-2 and COUP-TF2 in the adult mouse heart, and in situ hybridization of day 13.5 mouse embryos confirmed co-expression in the developing atria and ventricles (data not shown).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   A, diagram of COUP-TF2 and COUP-TF3 protein structure. The arrow and number indicate the first amino acid of each protein expressed by the library plasmid. The cartoons demonstrate the locations of the DNA-binding domain (DBD) and the ligand-binding domain (LBD). B, full-length COUP-TF2 co-immunoprecipitated with FOG-2. Extracts from COS-7 cells transfected with expression plasmids for FOG-2 (left two lanes), COUP-TF2 (middle two lanes), and FOG-2/COUP-TF2 (right two lanes) were subjected to immunoprecipitation (IP) with either preimmune (P) or immune (I) FOG-2 antisera. The proteins were separated by SDS-polyacrylamide gel electrophoresis and blotted on nitrocellulose. The membrane was then cut, and the lower half was probed by Western blotting (WB) with the anti-X-press antibody to detect recombinant COUP-TF2, whereas the upper half was probed with rabbit anti-FOG-2 antisera. A representative of four experiments is shown, demonstrating that COUP-TF2 was isolated only by co-immunoprecipitation with FOG-2.

The interaction of FOG-2 and COUP-TF2 was confirmed in mammalian cells by co-immunoprecipitation. COS-7 cells transfected with pcDNA3-FOG-2 expressed full-length FOG-2, which was immunoprecipitated by immune (I) FOG-2 antisera (Fig. 1B, lanes 2 and 6). X-press epitope-tagged COUP-TF2 was not immunoprecipitated by FOG-2 antisera (lane 4), rather, COUP-TF2 was only isolated after co-immunoprecipitation with FOG-2 (lane 6).

COUP-TF2 Interacts with Multiple FOG-2 Zinc Fingers-- To assess the relative binding of COUP-TF2 with the zinc fingers of FOG-2, we performed an in vitro binding assay with GST-FOG-2 fusion proteins. The COUP-TF2 in vitro translation product was selectively retained by GST-FOG-2 fusion proteins including the seventh and eight (F7-8) and the fifth and sixth (F5-6) zinc fingers to a greater extent than the sixth zinc finger (F6) or the first four zinc fingers (F1-4). COUP-TF2 was not retained by the fingerless amino terminus of FOG-2 or by GST alone (Fig. 2, top panel). This binding pattern differed from that of GATA4, which interacted equally well with all of the GST-FOG-2 fusion proteins containing zinc fingers (Fig. 2, middle panel). The most notable difference was the weak interaction of COUP-TF2 with zinc finger 6, whereas GATA4 interacted strongly with zinc finger 6. GST-FOG-2 fusion proteins did not retain [35S]methionine-labeled luciferase (Fig. 2, bottom panel).


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 2.   COUP-TF2 and GATA4 associate with the FOG-2 zinc fingers in vitro. Twenty percent of the [35S]methionine-labeled in vitro translation product used for binding is shown in the first lane. After the radiolabeled proteins had been incubated with immobilized GST or GST-FOG-2 fusion proteins, the beads were washed, and the bound input was eluted with sample buffer and subjected to 15% SDS-polyacrylamide gel electrophoresis. COUP-TF2 was selectively retained by GST-FOG-2 F7-8 and F5-6 to a greater extent than F6, F1-4, amino terminus (N-term), or GST. GATA4 was retained by all of the GST-FOG-2 proteins that included zinc fingers. The GST-FOG-2 fusion proteins did not retain luciferase. Coomassie Blue staining of the gel demonstrated strong expression of each GST protein (data not shown). A representative of three experiments is shown.

Interaction of COUP-TF2 with FOG-2 is Zinc Finger-dependent-- Because COUP-TF2 bound GST-FOG-2 fusion proteins containing zinc fingers, we hypothesized that this interaction required intact FOG-2 zinc fingers. In the mammalian two-hybrid system, the fifth and sixth zinc fingers of FOG-2(aa 497-831) (F5F6) fused to the GAL4 DNA-binding domain were tested for their ability to interact with COUP-TF2(117-414) fused to the VP16 transcriptional activation domain. Interaction of COUP-TF2(117-414) with F5F6 is demonstrated by an almost 4-fold activation of luciferase activity compared with GAL4 (Fig. 3). Next, plasmids encoding GAL4-FOG-2 cysteine-to-serine mutations selectively disrupting the fifth zinc finger (M5F6), sixth zinc finger (F5M6), and both the fifth and sixth zinc fingers (M5M6) were tested for interaction with VP16-COUP-TF2(117-414). Western blotting confirmed expression of each GAL4 fusion protein (data not shown). Mutation of the fifth zinc finger reduced the interaction of VP16-COUP-TF2(117-414) with GAL4-FOG-2(aa 497-831) by almost half, whereas mutation of finger 6 had less of an effect (Fig. 3). Mutation of both FOG-2 fingers 5 and 6 abolished the interaction. This finding demonstrates that FOG-2 zinc fingers are necessary for interaction with COUP-TF2.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 3.   The interaction of COUP-TF2 with FOG-2 requires FOG-2 zinc fingers. Site-directed polymerase chain reaction-based mutagenesis was used to introduce selective mutations of cysteine residues in FOG-2(aa 497-831) required for zinc finger formation. The mutant constructs were cloned into pM vector for expression as fusion proteins with the GAL4 DNA-binding domain. These plasmids were transiently transfected into NIH 3T3 cells with a plasmid encoding VP16-COUP-TF2(117-414) and a GAL4-responsive SV40 promoter luciferase reporter plasmid. The mean ± S.E. fold activation for each pM-FOG-2 construct co-transfected with pVP16-COUP-TF2(117-414) was normalized to the activity of the same plasmid co-transfected with pVP16. GAL4-FOG-2-F5F6 interacted with VP16-COUP-TF2(117-414) to a greater degree than the GAL4-FOG-2 zinc finger 6 mutant (F5M6) and the zinc finger 5 mutant (M5F6). Mutation of both zinc fingers abolished binding, which demonstrates that FOG-2 zinc fingers are required for COUP-TF2 interaction. Results from three experiments performed in triplicate are shown. *, a statistically significant (p < 0.05) interaction compared with GAL4.

FOG-2 Interacts with the Carboxyl Terminus of COUP-TF2-- We used the mammalian two-hybrid assay to further characterize the interaction of FOG-2 and COUP-TF2 in NIH 3T3 cells. GAL4-FOG-2(aa 497-831) significantly bound VP16-COUP-TF2(1-414) and VP16-COUP-TF2(117-414) (Fig. 4), whereas there was no interaction with VP16-COUP-TF2(1-335) or VP16-COUP-TF2(117-335). The carboxyl terminus of nuclear hormone receptors is required for ligand binding, dimerization, and interaction with corepressor and coactivator proteins (29). Crystallography has demonstrated that the tenth (H10) of 12 helices is required for dimerization and protein-protein interaction (30). Previous work has demonstrated that the introduction of three amino acid substitutions in H10 of COUP-TF2 greatly reduces DNA binding and repression activity (31). We reproduced the same mutations in VP16-COUP-TF2(117-414)-L363R-L364S-L367F (117-414 MUT) to test our hypothesis that H10 is required for FOG-2 interaction. VP16-COUP-TF2(117-414 MUT) did not interact with the fifth and sixth fingers of FOG-2, which further localizes the site of FOG-2 interaction within the COUP-TF2 ligand-binding domain.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 4.   GAL4-FOG-2(aa 497-831) interacts with VP16-COUP-TF2 in NIH 3T3 cells. The GAL4-SV40 promoter luciferase reporter plasmid was co-transfected into NIH 3T3 cells with pM-FOG-2(aa 497-831) and pVP16 plasmids encoding COUP-TF2 fusion proteins. The mean ± S.E. fold activation relative to VP16 from three experiments performed in triplicate is shown. *, a statistically significant (p < 0.05) difference in comparison with VP16 alone.

FOG-2 Interacts Specifically with COUP-TF1, COUP-TF2, and COUP-TF3-- In the absence of ligand, nuclear hormone receptors partner with specific corepressor proteins, which repress transcription (1). We performed in vitro binding assays with GST-FOG-2-F5-6 fusion protein to determine the specificity of interaction between FOG-2 and members of the COUP-TF and nuclear hormone family of proteins. The in vitro translation products of full-length GATA4, COUP-TF1, and COUP-TF3, but not those of RXRalpha , were selectively retained by GST-FOG-2-F5-6 compared with GST alone (Fig. 5A). Next, we used a yeast two-hybrid assay to test the interaction of FOG-2 with the ligand-binding domain of several nuclear hormone receptor proteins fused to the GAL4 transcriptional activation domain. A liquid beta -galactosidase assay provided a semiquantitative analysis of interaction in the AH109 yeast strain, which harbors a GAL4-responsive beta -galactosidase gene. GAL4-FOG-2(aa 497-831) selectively bound the ligand-binding domains of COUP-TF2 and COUP-TF3, but not with the ligand-binding domains of RXRalpha , PPARgamma , and GR (Fig. 5B). These results clearly demonstrate that FOG-2 selectively interacts with the COUP-TF family of orphan nuclear hormone receptors.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 5.   A, FOG-2 associates with COUP-TF1 and COUP-TF3 in vitro. Twenty percent of the translation product used for the binding assay was loaded on the left lane. GST-FOG-2-F5-6 selectively retained GATA4, COUP-TF1, and COUP-TF3 to a much greater extent than GST alone. B, FOG-2 interacts selectively with the ligand-binding domains of COUP-TF2 and COUP-TF3 in yeast. An AH109 culture transformed with pGAL4-BD-CAM-FOG-2(aa 497-831) was transformed with pACT2 plasmids encoding GAL4 transcriptional-activating domain fusion proteins with the ligand-binding domains of COUP-TF2, COUP-TF3, RXRalpha , GR, and PPAR-gamma . The liquid beta -galactosidase activity for each sample normalized to vector alone is shown. *, constructs that produced significantly more beta -galactosidase (p < 0.05) compared with vector alone. The mean ± S.E. from three experiments performed in triplicate is shown.

FOG-2 Enhances Repression Mediated by GAL4-COUP-TF2-- Because FOG-2 interacted with the COUP-TF2 repression domain, we hypothesized that COUP-TF2 may utilize FOG-2 as a corepressor protein. To prove this hypothesis, we fused fragments of COUP-TF2 to the GAL4 DNA-binding domain and tested their ability to repress transcription of a GAL4-responsive SV40 promoter luciferase reporter plasmid (kindly provided by M. Lazar (32)) in the presence or absence of FOG-2. Co-expression of FOG-2 with GAL4 did not significantly repress luciferase activity. However, GAL4-COUP-TF2(117-414) significantly repressed transcription 3.9 ± 0.1-fold (Fig. 6), and co-expression of FOG-2 markedly increased repression to 13.5 ± 1.1-fold (p < 0.0001, GAL4-COUP-TF2(117-414) vector versus FOG-2). GAL4-COUP-TF2(117-335) did not significantly repress luciferase activity, and co-expression of FOG-2 did not increase repression. Previous studies suggested that H10 of COUP-TF2 is required for COUP-TF2-dependent repression (30, 31, 33). In support of this, we found that the COUP-TF2 (117-414 MUT) H10 triple mutant did not repress luciferase activity, and co-expression of FOG-2 did not augment this repression. Western blotting confirmed expression of each GAL4 fusion protein (data not shown). These results demonstrate that COUP-TF2 can recruit FOG-2 as a corepressor protein.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 6.   COUP-TF2 uses FOG-2 as a corepressor protein. The GAL4-regulated SV40 promoter luciferase reporter plasmid has a high basal luciferase activity in 293 cells. We co-transfected plasmids encoding GAL4-COUP-TF2 proteins, and the reduction in luciferase activity relative to GAL4 alone is reported as fold repression. In the absence of FOG-2 (), only GAL4-COUP-TF2(117-414) significantly repressed luciferase activity. Removal of the carboxyl terminus and mutation of H10 resulted in a loss of repression activity. Co-expression of FOG-2 (black-square) with GAL4-COUP-TF2(117-414) markedly increased repression. **, constructs that caused significant repression (p < 0.0001) compared with GAL4 alone. The mean ± S.E. from three experiments is shown.

COUP-TF2 Synergistically Activates the ANF Promoter with GATA4-- COUP-TF2 is required for normal atrial development (27). To further investigate the role of COUP-TF2 in atrium-specific transcription, we examined the effect of COUP-TF2 on a rat ANF (-638 to +62)-promoter luciferase reporter plasmid (kindly provided by Kenneth R. Chien (34)). We found that GATA4 produced a significant activation of the ANF-luciferase reporter plasmid (mean ± S.E., 21.1 ± 1.4-fold; p = 0.028); in contrast, His-COUP-TF2 alone had little effect on ANF promoter activity (Fig. 7). Co-expression of full-length His-COUP-TF2 with GATA4 produced a synergistic dose-dependent activation of the ANF-luciferase reporter plasmid that was highly significant (up to 300-fold). The carboxyl-terminal deletion mutant His-COUP-TF2(1-335) did not influence GATA-dependent transcription (data not shown).


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 7.   COUP-TF2 increases the transcriptional activity of GATA4. CV-1 cells were co-transfected with the ANF(-638 to +62) luciferase reporter plasmid (34) and pcDNA3-beta -galactosidase to correct for differences in transfection efficiency. In the absence of GATA4 (), COUP-TF2 did not significantly activate the ANF luciferase reporter plasmid. In the presence of GATA4 (black-square), increasing amounts of pcDNA3.1/His-COUP-TF2 expression plasmid produced a marked induction of luciferase activity. For each category, the corrected luciferase activity was normalized to the average luciferase activity of the reporter plasmids co-transfected with vector alone. *, p < 0.05 compared with vector alone; **, p < 0.0001 compared with vector alone.

COUP-TF2 Is Necessary for FOG-2 Repression of GATA4-E215K-dependent Transcription-- Finally, we tested our hypothesis that FOG-2 could repress COUP-TF2-dependent transcription of a cardiac-specific promoter. As demonstrated previously (9, 22), co-transfection of FOG-2 repressed GATA4-dependent activation of the ANF promoter by 5.2-fold (Fig. 8A), whereas FOG-2 had no effect on the GATA4-E215K mutant (0.71-fold repression), which fails to interact with FOG-2 (22). FOG-2 repressed the GATA4-COUP-TF2-dependent synergistic activation of the ANF-luciferase reporter by 4.5-fold (155 ± 8.5 versus 34 ± 5.7; p < 0.0001; Fig. 8B). This finding showed that FOG-2 repressed ANF promoter activity; however it was not clear whether FOG-2 caused this repression by its interaction with GATA4, COUP-TF2, or both. To separate the effects of FOG-2 on COUP-TF2 from the effects of FOG-2 on GATA4, we used the GATA4-E215K mutant, which does not interact with FOG-2 (22). In the presence of COUP-TF2, FOG-2 repressed activation of ANF-luciferase by GATA4-E215K by 3.2-fold (197 ± 8.1 versus 62 ± 8.5; p < 0.0001; Fig. 8B). These results clearly demonstrated that FOG-2 can serve as a corepressor protein for COUP-TF2 on a cardiac-specific promoter.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 8.   A, FOG-2 does not repress GATA4-E215K-dependent transcription in CV-1 cells. Transient transfection in CV-1 cells was performed as described previously. In the absence of COUP-TF2, FOG-2 repressed GATA4-dependent (lane 4 versus lane 3) transcription of the ANF promoter but not GATA4-E215K-dependent (lane 6 versus lane 5) transcription of the ANF promoter. B, FOG-2 represses COUP-TF2-dependent synergistic activation of transcription by GATA4-E215K. 100 ng of pcDNA3.1/His-COUP-TF2(1-414) was co-transfected with each sample. Co-expression of COUP-TF2 with GATA4 produced a 7.1-fold increase in ANF-luciferase activity, and an 11.2-fold increase was produced with GATA4-E215K. FOG-2 significantly repressed the COUP-TF2-dependent synergistic luciferase activity for both GATA4 and GATA4-E215K.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In screening for novel interacting partners of FOG-2, the fifth and sixth zinc fingers of FOG-2 were used as bait because they are both CCHC zinc fingers that interact with the amino CCCC zinc finger of GATA4 (14). Our yeast-two hybrid screen isolated cDNA clones encoding the ligand-binding domains of both COUP-TF2 and COUP-TF3, which was unexpected because crystallography has not demonstrated a zinc finger within this region of nuclear receptors (30, 33). Because FOG-2 could not bind COUP-TF2 by a finger-finger interaction, we compared which FOG-2 zinc fingers bound GATA4 and COUP-TF2. In agreement with previously published studies (8, 14), GATA4 was retained well by GST-FOG-2 proteins encoding zinc finger 6, zinc fingers 7 and 8, and zinc fingers 1-4. COUP-TF2 was retained strongly by fingers 7 and 8, followed by zinc fingers 5 and 6, and COUP-TF2 was retained weakly by finger 6 alone and fingers 1-4 (Fig. 2). If COUP-TF2 interacted with the same zinc fingers as GATA4, with the same affinities, then we would have expected the same pattern of binding by GST-FOG-2 proteins. Our finding of distinct patterns of zinc finger interaction by COUP-TF2 and GATA4 is further supported by our mammalian two-hybrid analysis, which found that mutation of zinc finger 5 had a greater effect on VP16-COUP-TF2(117-414) binding than mutation of finger 6 (Fig. 3). These results demonstrate that GATA4 interacts with zinc finger 6 more strongly than with zinc finger 5, whereas COUP-TF2 clearly favors zinc finger 5 more than zinc finger 6. Whereas both GATA4 and COUP-TF2 can bind both zinc fingers 5 and 6, their relative affinity for different FOG-2 zinc fingers suggests the possibility that FOG-2 could interact with both proteins simultaneously.

The nuclear receptor ligand-binding domain serves as a molecular switch allowing ligand-induced conversion from transcriptional repression to activation (29). Ligand-binding domains are compact structures with a conserved architecture shaped by 10 helices forming a hydrophobic core tethered to the ligand-dependent transactivation domain, AF2, by the tenth helix, H10 (33). H10 is also a protein interaction surface, forming most of the interface for nuclear receptor dimers. Mutation of three leucine residues within the H10 of COUP-TF2 prevented FOG-2 binding (Fig. 4). This clearly demonstrates that FOG-2 interacts with the carboxyl terminus of COUP-TF2, a region that is also bound by other corepressor proteins. In addition to nuclear receptor-corepressor (N-Cor) and silencing mediator and thyroid hormone receptor (SMRT) (35), the COUP-TF2 ligand-binding domain binds Alien (36) and the nuclear receptor-corepressor variant RIP13Delta 1 (37) corepressor proteins. In the brain, COUP-TF1 is co-expressed with the zinc finger proteins CTIP1 and CTIP2, which bind COUP-TF1 and serve as corepressor proteins (38). We have demonstrated that FOG-2 selectively interacts with the ligand-binding domains of all three COUP-TF proteins, but not with RXRalpha , PPARgamma , or GR (Fig. 5). Besides differences in primary sequence (39), the lack of the second helix in the COUP-TF proteins (31) may alter the ligand-binding domain sufficiently to explain their selective interaction with FOG-2. Alien also selectively interacts with some, but not all, nuclear hormone receptors (36). The selective use of tissue-restricted corepressor proteins may be a mechanism by which widely expressed DNA-binding proteins can cause organ-specific transcription.

COUP-TF proteins repress transcription by binding directly to chromatin as a homodimer or heterodimer (40) (active repression) or after forming a dimer with a different member of the nuclear receptor family (transrepression) (25). Sequestration of coactivators into non-DNA-binding complexes by the COUP-TF proteins has also been proposed, but this mechanism of repression has been disputed (31). Active repression by COUP-TF1 requires the entire ligand-binding domain. Removal of H11, H12, and AF2 results in a loss of COUP-TF1-mediated repression, suggesting their role in binding corepressor proteins (35). Using GAL4-COUP-TF2 fusion proteins, we have demonstrated that deletion of the carboxyl terminus of COUP-TF2 abolishes active repression, FOG-2 interaction, and FOG-2-mediated repression. Within the ligand-binding domain, mutations of H1 disrupt binding by nuclear receptor-corepressor and silencing mediator and thyroid hormone receptor; however, H1 mutation likely changes the overall ligand-binding domain structure (33). The crystal structure of nuclear receptors has shown that H10 is an exposed protein-protein interaction surface (30). Mutation of the leucine residues performed in this study likely altered the conformation of H10 on the ligand-binding domain (33). We have demonstrated that this mutation decreases active repression by GAL4-COUP-TF2, suggesting that this site may also serve as a corepressor binding site. We found that mutation of H10 prevents FOG-2 binding, such that FOG-2 can no longer serve as a corepressor for COUP-TF2. Taken together our results are consistent with a model in which FOG-2 interacts with H10 as well as regions affected by H10 such as AF2, and that the FOG-2 binding site is also used by other corepressor proteins.

Although COUP-TF proteins are generally considered to be repressors of transcription, there are examples of COUP-TF-dependent transcriptional activation (41, 42). Direct promoter binding by COUP-TF is required for complete induction of phosphoenolpyruvate carboxykinase gene transcription by glucocorticoids (43, 44). COUP-TF1 binds Sp1 to activate the NFGI-A gene expression (45). The molecular mechanism of COUP-TF-mediated activation includes binding of steroid receptor activator 1 and p300 coactivator proteins to the carboxyl terminus of COUP-TF1 (45). To our knowledge, we now report for the first time the synergistic activation of the cardiac-specific ANF promoter by GATA4 and COUP-TF2. There are several potential mechanisms that may explain the synergistic activation of the ANF promoter by COUP-TF2 and GATA4, and this is the subject of active work.

FOG-2 repressed COUP-TF2-dependent synergistic activation of the ANF promoter by GATA4. This result left open the possibility that FOG-2 repressed the synergistic activation solely by binding GATA4. To separate the ability of FOG-2 to repress GATA4-dependent transcription from its effects on COUP-TF2, we used the GATA4-E215K mutant, which does not interact with FOG-2 (22). We show that FOG-2 can repress GATA4-dependent but not GATA4-E215K-dependent transcriptional activation of the ANF promoter. However, FOG-2 repressed transcriptional activation by GATA4-E215K in the presence of COUP-TF2, which demonstrates that FOG-2 can serve as a corepressor protein for COUP-TF2 on a cardiac-specific promoter. It is noteworthy that FOG-2 repression of GATA4-E215K/COUP-TF2 transcription was not complete. Crispino et al. (46) created mice harboring the GATA4-V217G mutation (numbering differs from the published report, reflecting mouse GATA4 sequence in GenBank accession number NP  032118), which produces a GATA4 mutant that does not interact with FOG (46). Mice homozygous for this mutation resembled the FOG-2-deficient mice, yet there were differences in eHAND expression and orientation of the outflow tracts. The incomplete phenocopy of the GATA4-V217G knock-in and the FOG-2 knock-out may reflect an interaction of GATA4 with a different FOG protein (46), yet our results raise the possibility that FOG-2 may be interacting with COUP-TF2 in concert with GATA4.

In summary, we have demonstrated the interaction of FOG-2 with a transcriptional regulator other than the GATA proteins. The physiologic importance of this interaction is underscored by the finding that FOG-2-null and COUP-TF2-null mice have defects related to mesenchymal-epithelial and -endothelial interactions, which are important for heart and blood vessel formation. We have demonstrated preferential binding of different zinc fingers by COUP-TF2 and GATA4. COUP-TF2 can utilize FOG-2 as a corepressor protein to down-regulate transcription from both a heterologous promoter and a cardiac-specific promoter. Taken together, these results suggest that FOG-2 interacts with multiple cardiac transcription factors to regulate the complex program of cardiac morphogenesis.

    ACKNOWLEDGEMENTS

We greatly appreciate the support provided by members of the Leiden laboratory and their careful review of and suggestions on the manuscript.

    FOOTNOTES

* This work was supported by Mentored Clinical Scientist Development Award K08 HL03667-01A1 and Grant R01 HL54592-06 from the National Institutes of Health and Beginning Grant-in-Aid 0060313T from the American Heart Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Cardiovascular Biology Laboratory, Harvard School of Public Health, 677 Huntington Ave., Boston, MA 02115. Tel.: 617-432-4994; Fax: 617-432-2980; E-mail: huggins@cvlab.harvard.edu.

Published, JBC Papers in Press, May 29, 2001, DOI 10.1074/jbc.M103577200

    ABBREVIATIONS

The abbreviations used are: FOG, Friend of GATA; COUP-TF, chicken ovalbumin upstream promoter-transcription factor; ANF, atrial natriuretic factor; RXRalpha , retinoid X receptor alpha ; GR, glucocorticoid receptor; PPARgamma , peroxisome proliferating antigen receptor gamma ; CCCC, CCHC, and CCHH, zinc finger subtypes in which a zinc atom is coordinated by cysteine (C) or histidine (H) side chains; aa, amino acid(s); GST, glutathione S-transferase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Collingwood, T. N., Urnov, F. D., and Wolffe, A. P. (1999) J. Mol. Endocrinol. 23, 255-275
2. Tsang, A. P., Visvader, J. E., Turner, C. A., Fujiwara, Y., Yu, C., Weiss, M. J., Crossley, M., and Orkin, S. H. (1997) Cell 90, 109-119
3. Tsang, A. P., Fujiwara, Y., Hom, D. B., and Orkin, S. H. (1998) Genes Dev. 12, 1176-1188
4. Deconinck, A. E., Mead, P. E., Tevosian, S. G., Crispino, J. D., Katz, S. G., Zon, L. I., and Orkin, S. H. (2000) Development (Camb.) 127, 2031-2040
5. Tevosian, S. G., Deconinck, A. E., Tanaka, M., Schinke, M., Litovsky, S. H., Izumo, S., Fujiwara, Y., and Orkin, S. H. (2000) Cell 101, 729-739
6. Svensson, E. C., Huggins, G. S., Lin, H., Clendenin, C., Jiang, F., Tufts, R., Dardik, F. B., and Leiden, J. M. (2000) Nat. Genet. 25, 353-356
7. Matthews, J. M., Kowalski, K., Liew, C. K., Sharpe, B. K., Fox, A. H., Crossley, M., and MacKay, J. P. (2000) Eur. J. Biochem. 267, 1030-1038
8. Fox, A. H., Liew, C., Holmes, M., Kowalski, K., Mackay, J., and Crossley, M. (1999) EMBO J. 18, 2812-2822
9. Svensson, E. C., Tufts, R. L., Polk, C. E., and Leiden, J. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 956-961
10. Tevosian, S. G., Deconinck, A. E., Cantor, A. B., Rieff, H. I., Fujiwara, Y., Corfas, G., and Orkin, S. H. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 950-955
11. Lu, J. R., McKinsey, T. A., Xu, H., Wang, D. Z., Richardson, J. A., and Olson, E. N. (1999) Mol. Cell. Biol. 19, 4495-4502
12. Durocher, D., Charron, F., Warren, R., Schwartz, R. J., and Nemer, M. (1997) EMBO J. 16, 5687-5696
13. Lee, Y., Shioi, T., Kasahara, H., Jobe, S. M., Wiese, R. J., Markham, B. E., and Izumo, S. (1998) Mol. Cell. Biol. 18, 3120-3129
14. Fox, A. H., Kowalski, K., King, G. F., Mackay, J. P., and Crossley, M. (1998) J. Biol. Chem. 273, 33595-33603
15. Cheng, G., Hagen, T. P., Dawson, M. L., Barnes, K. V., and Menick, D. R. (1999) J. Biol. Chem. 274, 12819-12826
16. Ip, H. S., Wilson, D. B., Heikinheimo, M., Tang, Z., Ting, C. N., Simon, M. C., Leiden, J. M., and Parmacek, M. S. (1994) Mol. Cell. Biol. 14, 7517-7526
17. Lien, C. L., Wu, C., Mercer, B., Webb, R., Richardson, J. A., and Olson, E. N. (1999) Development (Camb.) 126, 75-84
18. Searcy, R. D., Vincent, E. B., Liberatore, C. M., and Yutzey, K. E. (1998) Development (Camb.) 125, 4461-4470
19. Rosoff, M. L., and Nathanson, N. M. (1998) J. Biol. Chem. 273, 9124-9129
20. Kuo, C. T., Morrisey, E. E., Anandappa, R., Sigrist, K., Lu, M. M., Parmacek, M. S., Soudais, C., and Leiden, J. M. (1997) Genes Dev. 11, 1048-1060
21. Molkentin, J. D., Lin, Q., Duncan, S. A., and Olson, E. N. (1997) Genes Dev. 11, 1061-1072
22. Svensson, E. C., Huggins, G. S., Dardik, F. B., Polk, C. E., and Leiden, J. M. (2000) J. Biol. Chem. 275, 20762-20769
23. Fossett, N., Zhang, Q., Gajewski, K., Choi, C. Y., Kim, Y., and Schulz, R. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7348-7353
24. Wang, L. H., Tsai, S. Y., Cook, R. G., Beattie, W. G., Tsai, M. J., and O'Malley, B. W. (1989) Nature 340, 163-166
25. Tsai, S. Y., and Tsai, M. J. (1997) Endocr. Rev. 18, 229-240
26. Jonk, L. J., de Jonge, M. E., Pals, C. E., Wissink, S., Vervaart, J. M., Schoorlemmer, J., and Kruijer, W. (1994) Mech. Dev. 47, 81-97
27. Pereira, F. A., Qiu, Y., Zhou, G., Tsai, M. J., and Tsai, S. Y. (1999) Genes Dev. 13, 1037-1049
28. Huggins, G. S., Chin, M. T., Sibinga, N. E., Lee, S. L., Haber, E., and Lee, M. E. (1999) J. Biol. Chem. 274, 28690-28696
29. Perlmann, T., and Evans, R. M. (1997) Cell 90, 391-397
30. Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., and Moras, D. (1995) Nature 375, 377-382
31. Achatz, G., Holzl, B., Speckmayer, R., Hauser, C., Sandhofer, F., and Paulweber, B. (1997) Mol. Cell. Biol. 17, 4914-4932
32. Huang, E. Y., Zhang, J., Miska, E. A., Guenther, M. G., Kouzarides, T., and Lazar, M. A. (2000) Genes Dev. 14, 45-54
33. Wurtz, J. M., Bourguet, W., Renaud, J. P., Vivat, V., Chambon, P., Moras, D., and Gronemeyer, H. (1996) Nat. Struct. Biol. 3, 87-94
34. Knowlton, K. U., Baracchini, E., Ross, R. S., Harris, A. N., Henderson, S. A., Evans, S. M., Glembotski, C. C., and Chien, K. R. (1991) J. Biol. Chem. 266, 7759-7768
35. Shibata, H., Nawaz, Z., Tsai, S. Y., O'Malley, B. W., and Tsai, M. J. (1997) Mol. Endocrinol. 11, 714-724
36. Dressel, U., Thormeyer, D., Altincicek, B., Paululat, A., Eggert, M., Schneider, S., Tenbaum, S. P., Renkawitz, R., and Baniahmad, A. (1999) Mol. Cell. Biol. 19, 3383-3394
37. Bailey, P. J., Dowhan, D. H., Franke, K., Burke, L. J., Downes, M., and Muscat, G. E. (1997) J. Steroid Biochem. Mol. Biol. 63, 165-174
38. Avram, D., Fields, A., Pretty On Top, K., Nevrivy, D. J., Ishmael, J. E., and Leid, M. (2000) J. Biol. Chem. 275, 10315-10322
39. Qiu, Y., Krishnan, V., Pereira, F. A., Tsai, S. Y., and Tsai, M. J. (1996) J. Steroid Biochem. Mol. Biol. 56, 81-85
40. Avram, D., Ishmael, J. E., Nevrivy, D. J., Peterson, V. J., Lee, S. H., Dowell, P., and Leid, M. (1999) J. Biol. Chem. 274, 14331-14336
41. Power, S. C., and Cereghini, S. (1996) Mol. Cell. Biol. 16, 778-791
42. Lazennec, G., Kern, L., Valotaire, Y., and Salbert, G. (1997) Mol. Cell. Biol. 17, 5053-5066
43. Scott, D. K., Mitchell, J. A., and Granner, D. K. (1996) J. Biol. Chem. 271, 31909-31914
44. Hall, R. K., Sladek, F. M., and Granner, D. K. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 412-416
45. Pipaon, C., Tsai, S. Y., and Tsai, M. J. (1999) Mol. Cell. Biol. 19, 2734-2745
46. Crispino, J. D., Lodish, M. B., Thurberg, B. L., Litovsky, S. H., Collins, T., Molkentin, J. D., and Orkin, S. H. (2001) Genes Dev. 15, 839-844


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. D. Clugston, W. Zhang, and J. J. Greer
Gene expression in the developing diaphragm: significance for congenital diaphragmatic hernia
Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L665 - L675.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. Matsushita, S. Sasaki, Y. Kashiwabara, K. Nagayama, K. Ohba, H. Iwaki, H. Misawa, K. Ishizuka, and H. Nakamura
Essential Role of GATA2 in the Negative Regulation of Thyrotropin {beta} Gene by Thyroid Hormone and Its Receptors
Mol. Endocrinol., April 1, 2007; 21(4): 865 - 884.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
K. G. Ackerman, J. Wang, L. Luo, Y. Fujiwara, S. H. Orkin, and D. R. Beier
Gata4 Is Necessary for Normal Pulmonary Lobar Development
Am. J. Respir. Cell Mol. Biol., April 1, 2007; 36(4): 391 - 397.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. G. Gardner, S. Chen, D. J. Glenn, and C. L. Grigsby
Molecular Biology of the Natriuretic Peptide System: Implications for Physiology and Hypertension
Hypertension, March 1, 2007; 49(3): 419 - 426.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Hamik, B. Wang, and M. K. Jain
Transcriptional Regulators of Angiogenesis
Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 1936 - 1947.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. C. Lin, A. E. Roche, J. Wilk, and E. C. Svensson
The N Termini of Friend of GATA (FOG) Proteins Define a Novel Transcriptional Repression Motif and a Superfamily of Transcriptional Repressors
J. Biol. Chem., December 31, 2004; 279(53): 55017 - 55023.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. L. Clabby, T. A. Robison, H. F. Quigley, D. B. Wilson, and D. P. Kelly
Retinoid X Receptor alpha Represses GATA-4-mediated Transcription via a Retinoid-dependent Interaction with the Cardiac-enriched Repressor FOG-2
J. Biol. Chem., February 14, 2003; 278(8): 5760 - 5767.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. E. Reese, T. Mikawa, and D. M. Bader
Development of the Coronary Vessel System
Circ. Res., November 1, 2002; 91(9): 761 - 768.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
N. M. Robert, J. J. Tremblay, and R. S. Viger
Friend of GATA (FOG)-1 and FOG-2 Differentially Repress the GATA-Dependent Activity of Multiple Gonadal Promoters
Endocrinology, October 1, 2002; 143(10): 3963 - 3973.
[Abstract] [Full Text] [PDF]